Study Evaluating Single Doses of BLI-489 in Healthy Subjects

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy Subjects

In brief

The purpose of this study is to evaluate the safety, and tolerability of single doses of BLI-489 administered intravenously in healthy subjects, and also how the drug is absorbed and eliminated.

Key facts

Study ID

NCT00820404

Run by

Wyeth is now a wholly owned subsidiary of Pfizer

People needed

54

Starts

2009-01-01

Expected to finish

2009-04-01

Last updated by the study team

2009-07-17

Who can join

Age: 20 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Men or women of nonchildbearing potential, 18 to 50 years of age inclusive at screening.
• Body mass index (BMI) in the range of 18 to 32 kg/m2 and body weight greater than or equal to 50 kg.
• Healthy as determined by the investigator on the basis of the screening evaluations.
• Nonsmoker of smoker of fewer than 10 cigarettes per day as determined by history.

You may not qualify if…

• Presence of history of any disorder that may prevent the successful completion of the study.
• History of drug abuse within 1 year.

Where it is running

• Study site — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.